Anemia in Dogs and Cats With Kidney Disease: Signs, Diagnosis and Treatment

Anemia in Dogs and Cats With Kidney Disease: Signs, Diagnosis and Treatment

By Dr Duncan Houston

A dog or cat with chronic kidney disease may become quieter, weaker and less interested in food as their red blood cell count falls. These changes are easily blamed on the kidney disease itself, ageing or a generally bad week.

Renal anemia is treatable, but it should not be diagnosed from one low hematocrit result alone. Kidney disease commonly contributes to anemia, particularly in its later stages, but blood loss, inflammation, infection, iron deficiency, cancer and bone marrow disease can occur at the same time.

The most important questions are whether the anemia is genuinely caused by the kidneys, whether treatment should begin now and whether the patient needs gradual red blood cell support or an immediate transfusion.

Quick Answer

Renal anemia is usually a nonregenerative anemia caused mainly by reduced production of erythropoietin, the kidney hormone that tells the bone marrow to make red blood cells. Iron restriction, inflammation, shortened red blood cell survival and blood loss can make it worse.

Current IRIS guidance recommends treating CKD-associated anemia when hematocrit is below 25% in cats or below 30% in dogs. Persistent CKD-associated anemia between 25% and 28% in cats, or between 30% and 35% in dogs, should also be treated. These are treatment thresholds, not automatic transfusion thresholds.

What Is Renal Anemia?

Anemia means there are too few circulating red blood cells, too little hemoglobin or both.

Red blood cells carry oxygen from the lungs to the rest of the body. When their number falls, the heart and lungs must work harder to deliver enough oxygen to organs, muscles and the brain.

Renal anemia is anemia caused primarily by chronic kidney disease. It is usually described as:

• Nonregenerative, meaning the bone marrow is not producing enough replacement red blood cells

• Normocytic, meaning the cells are usually relatively normal in size

• Normochromic, meaning they initially contain a relatively normal concentration of hemoglobin

This pattern is typical, but not absolute. Iron deficiency, chronic blood loss or several simultaneous diseases can change the size and appearance of the red blood cells.

Why Does Kidney Disease Cause Anemia?

Chronic kidney disease can reduce red blood cell mass through several mechanisms.

Reduced erythropoietin production

The kidneys produce erythropoietin, commonly shortened to EPO.

When oxygen delivery falls, healthy kidneys release EPO into the bloodstream. EPO travels to the bone marrow and stimulates immature red blood cell precursors to develop into functioning red blood cells.

As functional kidney tissue is lost and the renal interstitium becomes fibrotic, the kidney may no longer produce an appropriate EPO response. The bone marrow still has the ability to make red blood cells, but it is not receiving enough stimulation.

This is the main mechanism behind renal anemia.

Shortened red blood cell lifespan

Uremic toxins can damage circulating red blood cells and shorten how long they survive.

A normal red blood cell population is constantly being replaced. When cells are lost earlier than expected and the bone marrow is also receiving inadequate EPO stimulation, anemia becomes progressively worse.

Functional iron deficiency

A patient can have iron stored within the body but still be unable to use it efficiently.

Chronic inflammation increases hepcidin, a hormone that reduces intestinal iron absorption and traps iron inside storage cells. The bone marrow may therefore struggle to obtain enough usable iron even when total body stores are not completely depleted.

This is called functional iron deficiency. It differs from absolute iron deficiency, in which total body iron stores are genuinely low. Both may occur in CKD.

Chronic inflammation or infection

Inflammatory cytokines can suppress bone marrow activity and interfere with both EPO responsiveness and iron availability.

Concurrent problems may include:

• Urinary tract infection

• Pyelonephritis

• Dental disease

• Pancreatitis

• Chronic intestinal inflammation

• Cancer

• Other systemic inflammatory disease

A patient may therefore have anemia caused by both CKD and chronic inflammation.

Blood loss

Slow blood loss may occur because of:

• Gastrointestinal bleeding

• Urinary tract bleeding

• Severe parasite infestation

• A bleeding tumour

• Abnormal platelet function associated with uremia

• Repeated blood sampling

• Surgery or another procedure

Gastric ulceration should not be assumed in every CKD patient. Black stool, falling red blood cell values, iron deficiency or other evidence of gastrointestinal bleeding should prompt a specific investigation rather than automatic long-term acid suppression.

Inadequate nutrition

Reduced appetite, nausea and food aversion can contribute to:

• Protein-calorie malnutrition

• Iron deficiency

• Vitamin deficiencies

• Muscle loss

• Reduced ability to recover from illness

Nutrition alone rarely corrects true EPO-deficiency anemia, but poor intake can make the anemia and overall CKD substantially harder to manage.

How Common Is Anemia in Chronic Kidney Disease?

The likelihood of anemia increases as kidney disease becomes more advanced.

IRIS reports that CKD-associated anemia is usually most clinically important in later-stage disease, although it can occasionally occur earlier. A markedly low hematocrit in a well-hydrated dog or cat with only Stage 2 CKD should therefore trigger a search for another cause rather than being blamed automatically on the kidneys.

This point matters in practice. A Stage 2 cat with a hematocrit of 20% may have CKD, but the severity of the anemia is too great to assume that moderate kidney disease explains everything. Blood loss, infection, inflammation, haemolysis, FeLV, cancer and bone marrow disease may be more important.

What Are the Signs of Renal Anemia?

Mild anemia may produce no obvious signs.

Because CKD-associated anemia usually develops gradually, the body may partially adapt. Owners may not recognise the change until they compare the pet’s current activity with how they behaved several months earlier.

Common signs include:

• Pale gums

• Reduced energy

• Sleeping more

• Weakness

• Reduced interest in walks or play

• Difficulty climbing stairs

• Reduced ability to jump

• Poor appetite

• Weight loss

• Muscle loss

• Faster breathing

• Faster heart rate

• A new heart murmur

• Feeling cold

• Pica, including licking or eating unusual materials

• Collapse in severe cases

Anemia can also worsen signs already associated with CKD, including appetite loss, lethargy and exercise intolerance. Moderate to severe anemia has been associated with poorer quality-of-life scores in cats with CKD.

What do anemic gums look like?

Normal gum colour varies between animals, but healthy gums are generally pink.

Concerning changes include:

• Very pale pink gums

• White or nearly white gums

• Pale inner eyelids

• Pale tongue

• Poor colour returning after pressure is released

Some cats and dogs have naturally darkly pigmented gums. In these patients, the tongue, inner eyelids or unpigmented oral tissues may be easier to assess.

Gum colour cannot determine the exact hematocrit. A pet with pale gums still needs a blood test.

Does Anemia Cause Fast Breathing?

It can.

When the blood carries less oxygen, the body may compensate by increasing:

• Heart rate

• Breathing rate

• Cardiac output

Mildly increased breathing may occur with significant anemia, but laboured breathing should never be attributed casually to a low red blood cell count. Heart failure, pleural fluid, pneumonia, pulmonary bleeding, pain and other respiratory emergencies must also be considered.

Open-mouth breathing in a cat is an emergency.

How Worried Should You Be?

Risk level	What you may notice	What it may mean	What to do
Mild or stable	Slightly reduced hematocrit, normal appetite, normal breathing and reasonable energy	Early anemia, laboratory variation or a stable chronic change	Confirm the trend and investigate the cause
Treatment range	Persistent hematocrit of 25% to 28% in a cat or 30% to 35% in a dog, with CKD considered the main cause	Current IRIS guidance supports treatment	Discuss an anemia treatment plan with your veterinarian
Significant anemia	Hematocrit below 25% in a cat or below 30% in a dog, with lethargy, poor appetite or weakness	Reduced red blood cell mass is likely affecting wellbeing	Begin treatment and investigate contributing disease promptly
Severe or urgent	Marked weakness, very pale gums, rapid heart rate, reduced appetite, rapid breathing or a rapidly falling hematocrit	Significant oxygen-delivery compromise or active blood loss may be present	Seek same-day veterinary assessment
Critical	Collapse, inability to stand, breathing distress, reduced consciousness, severe bleeding or seizures	Life-threatening anemia or another emergency	Go to an emergency veterinary hospital immediately

The IRIS hematocrit recommendations are intended to identify when CKD-associated anemia should be treated. They do not mean that every cat below 25% or every dog below 30% needs an immediate blood transfusion.

Is There a Specific PCV That Requires a Blood Transfusion?

No universal PCV or hematocrit number automatically triggers transfusion.

The decision depends on:

• Clinical signs

• Speed of decline

• Active bleeding

• Heart rate

• Breathing

• Blood pressure

• Cardiovascular disease

• Ability to stand and function

• Whether longer-term treatment has had time to work

• Whether the patient is becoming unstable

A CKD patient that has slowly adapted to a hematocrit of 17% may appear more stable than a patient whose hematocrit has fallen rapidly from 35% to 20% after acute bleeding.

The patient is treated, not simply the laboratory number.

How Is Renal Anemia Diagnosed?

Diagnosis requires more than confirming that a CKD patient has a low PCV.

The veterinary team must determine whether the anemia is:

• Real

• Regenerative or nonregenerative

• Consistent with kidney disease

• Being worsened by another condition

• Severe enough to require immediate intervention

1. Complete Blood Count

A complete blood count evaluates:

• Hematocrit

• Packed cell volume

• Hemoglobin

• Red blood cell count

• Red blood cell size

• Hemoglobin concentration

• White blood cells

• Platelets

PCV and hematocrit are closely related measurements of the proportion of blood made up of red blood cells. They are often used interchangeably in clinical discussion, although the laboratory methods differ.

The complete blood count also reveals whether anemia is isolated or whether white blood cells and platelets are abnormal too. Multiple abnormal cell lines raise greater concern about bone marrow disease, cancer, infection or a severe systemic process.

2. Reticulocyte Count

Reticulocytes are young red blood cells recently released by the bone marrow.

An increased absolute reticulocyte count means that the marrow is responding to anemia. This occurs with conditions such as blood loss or red blood cell destruction.

A low or inadequate reticulocyte response supports nonregenerative anemia.

Renal anemia is usually nonregenerative because the bone marrow is not receiving sufficient EPO stimulation. However, recent bleeding, transfusion or early recovery can complicate interpretation.

3. Blood Smear Examination

A blood smear allows direct assessment of:

• Red blood cell shape

• Cell size

• Polychromasia

• Agglutination

• Red blood cell fragments

• Blood parasites

• Abnormal white blood cells

• Platelet numbers

• Evidence of bone marrow stress or cancer

The smear may reveal clues suggesting haemolysis, blood loss, infection or another diagnosis rather than uncomplicated renal anemia.

4. Hydration Assessment

Dehydration concentrates the blood and can make the hematocrit appear higher than it truly is.

After fluid therapy, the measured hematocrit may fall because the circulation has been rehydrated and the red blood cells are no longer artificially concentrated.

This does not necessarily mean that fluid therapy has caused new anemia. It may have revealed the patient’s true red blood cell mass.

Hematocrit should therefore be interpreted alongside:

• Hydration

• Total protein

• Albumin

• Recent fluid therapy

• Body weight

• Clinical examination

5. Kidney Assessment

The CKD assessment may include:

• Creatinine

• SDMA

• Urea

• Phosphorus

• Potassium

• Bicarbonate or total carbon dioxide

• Urinalysis

• Urine protein-to-creatinine ratio

• Urine culture when indicated

• Blood pressure

• Diagnostic imaging

Kidney stage and anemia severity should make clinical sense together.

Current IRIS guidance specifically advises looking for another disease process when a well-hydrated Stage 2 cat has a hematocrit below 25%, or a well-hydrated Stage 2 dog has a hematocrit below 30%.

6. Iron Assessment

Possible tests include:

• Serum iron

• Total iron-binding capacity

• Transferrin saturation

• Ferritin

• Reticulocyte hemoglobin content

• Red blood cell indices

• Bone marrow iron staining in selected cases

No one blood result perfectly distinguishes absolute from functional iron deficiency in a CKD patient.

Serum iron alone is particularly unreliable. Ferritin can rise during inflammation, while transferrin can fall, making apparently reassuring results difficult to interpret.

Transferrin saturation and reticulocyte hemoglobin may provide additional information, but specialist interpretation may still be needed.

7. Investigation for Blood Loss

The veterinary team may look for:

• Black, tar-like stool

• Fresh gastrointestinal bleeding

• Blood in urine

• Fleas or other parasites

• Oral bleeding

• A bleeding tumour

• Recent surgery

• Repeated blood sampling

• A clotting disorder

Testing may include:

• Faecal examination

• Urinalysis

• Abdominal imaging

• Coagulation tests

• Gastrointestinal imaging

• Endoscopy in selected patients

• Iron studies

Long-term acid suppressants or sucralfate are not routine treatments for every CKD patient. They are used when there is evidence or strong suspicion of gastrointestinal disease, ulceration, bleeding or reflux-related injury.

8. Investigation for Haemolysis

Red blood cell destruction may produce:

• Jaundice

• Dark urine

• Rapidly falling hematocrit

• Increased bilirubin

• Spherocytes

• Agglutination

• Regenerative changes

• Fever

• An enlarged spleen

Possible causes include:

• Immune-mediated haemolytic anemia

• Blood parasites

• Oxidative injury

• Toxins

• Transfusion reaction

• Infection

Haemolytic anemia requires a different treatment pathway from renal anemia.

9. Infectious Disease Testing

Testing depends on species, geography and exposure history.

Possible tests include:

Dogs

• Ehrlichia

• Anaplasma

• Babesia

• Heartworm disease

• Leishmania in relevant regions

• Other vector-borne infection

Cats

• Feline leukaemia virus

• Feline immunodeficiency virus

• Haemotropic Mycoplasma

• Other infections selected according to history

Infection can cause anemia directly, suppress the bone marrow or reduce the response to erythropoiesis treatment.

10. Bone Marrow Sampling

Bone marrow aspiration or biopsy is not required for every CKD patient with anemia.

It becomes more useful when:

• The anemia is unexpectedly severe for the CKD stage

• White blood cells or platelets are also low

• Abnormal circulating cells are present

• The reticulocyte response is absent despite treatment

• Darbepoetin initially works and then the anemia becomes substantially worse

• Cancer or marrow failure is suspected

• The diagnosis remains uncertain after routine investigation

Bone marrow testing can identify leukaemia, lymphoma, myelofibrosis, aplasia, myelodysplasia and pure red cell aplasia.

What Else Can Cause Anemia in a Dog or Cat With CKD?

A CKD diagnosis does not protect a pet from collecting another disease. In older animals, concurrent conditions are common.

Important differential diagnoses include:

Chronic blood loss

Possible sources include the gastrointestinal tract, urinary tract, parasites, surgery or a bleeding tumour.

Chronic blood loss commonly produces iron deficiency and may eventually cause small, pale red blood cells.

Anemia of inflammation

Infection, pancreatitis, dental disease, cancer and chronic inflammatory disorders can suppress red blood cell production and restrict iron availability.

Bone marrow disease

Leukaemia, lymphoma, myeloma, metastatic cancer, myelofibrosis and aplastic disease can all produce nonregenerative anemia.

Immune-mediated haemolytic anemia

This causes immune destruction of circulating red blood cells and is often regenerative once the bone marrow has had time to respond.

Medication or toxin exposure

Potential causes include:

• Chemotherapy

• Oestrogen exposure

• Some antibiotics

• Certain anticonvulsants

• Oxidant toxins

• Onion or garlic exposure

• Zinc

• Other marrow-toxic substances

Infectious disease

Vector-borne infections and feline retroviruses can cause or worsen anemia.

Nutritional deficiency

Iron deficiency is the main nutritional concern, although severe or prolonged malnutrition may involve several nutrients.

Repeated blood sampling

Small individual samples may appear insignificant, but repeated phlebotomy can contribute meaningfully to anemia in a small cat or dog with advanced CKD.

IRIS specifically recommends evaluating contributing factors such as infection and excessive blood sampling before assuming the anemia is caused only by kidney disease.

How Is Renal Anemia Treated?

Treatment has four broad goals:

1. Correct immediately dangerous anemia.

2. Stimulate new red blood cell production.

3. Ensure enough usable iron is available.

4. Identify and treat other causes contributing to the anemia.

Treat Contributing Problems First

Possible interventions include:

• Treating infection

• Controlling gastrointestinal bleeding

• Treating parasites

• Improving calorie and protein intake

• Correcting iron deficiency

• Reviewing marrow-suppressive medication

• Minimising unnecessary blood collection

• Managing inflammation

• Treating cancer or another systemic disease

Renal anemia treatment is less likely to work when an ongoing source of blood loss, infection or severe inflammation remains unaddressed.

Blood Transfusion

A red blood cell transfusion provides immediate improvement in oxygen-carrying capacity.

It may be used when the patient has:

• Severe symptomatic anemia

• Collapse

• Cardiovascular instability

• Significant active bleeding

• Marked breathing changes

• Profound weakness

• Acute deterioration before slower medication can work

• An upcoming urgent procedure that cannot be delayed

Packed red blood cells are often preferred when the main problem is anemia because they provide red blood cells with less fluid volume than whole blood.

A transfusion is a bridge, not a cure for EPO deficiency. The donated cells have a limited lifespan, and longer-term treatment is usually needed if CKD remains the underlying cause.

What are the risks of transfusion?

Potential complications include:

• Fever

• Allergic reaction

• Haemolytic reaction

• Fluid overload

• Lung injury

• Transmission of infection

• Delayed destruction of transfused cells

Cats have naturally occurring blood-group antibodies, so blood typing is essential and crossmatching may also be required. Dogs should also be typed and appropriately crossmatched according to transfusion history and clinical circumstances.

Darbepoetin

Darbepoetin is a long-acting human erythropoietin analogue.

It stimulates the bone marrow to make more red blood cells and has been used extra-label in both dogs and cats with CKD-associated anemia.

Darbepoetin is generally preferred to older epoetin products because it appears less likely to cause antibody formation and pure red cell aplasia, although the risk is not zero. It is not formally approved for dogs or cats by the FDA.

How is darbepoetin given?

IRIS lists a veterinary starting range of approximately 0.45 to 1 microgram/kg by subcutaneous injection once weekly during induction. Once a suitable response is achieved, the interval may be extended according to the patient’s CBC and clinical response.

This is a veterinarian-managed protocol. The dose should not be calculated or adjusted at home without laboratory monitoring.

How quickly does darbepoetin work?

Darbepoetin does not replace red blood cells immediately.

The bone marrow needs time to produce and release new cells.

In one retrospective feline study:

• 14 of 25 cats responded

• Responding cats took a median of approximately 21 days

• Vomiting, hypertension, seizures and fever were reported as possible adverse effects

In a canine study:

• 28 of 33 dogs reached a PCV of at least 30%

• Median time to reach that response was 29 days

• Increased blood pressure, seizures and possible pure red cell aplasia were reported

These studies were retrospective and treatment protocols varied, but they show that meaningful improvement commonly takes several weeks rather than several days.

What are the risks of darbepoetin?

Potential adverse effects include:

• Hypertension

• Seizures or other neurological events

• Polycythemia

• Iron depletion

• Vomiting

• Fever

• Injection reactions

• Pure red cell aplasia

Blood pressure should be monitored because hypertension is common in CKD and may worsen during treatment.

What is pure red cell aplasia?

Pure red cell aplasia, or PRCA, is a serious immune reaction in which antibodies target the administered human EPO product and may also neutralise the animal’s own erythropoietin.

Warning signs include:

• Initial improvement followed by worsening anemia

• An extremely low reticulocyte count

• Severe nonregenerative anemia

• Failure to respond despite increasing treatment

• Bone marrow showing very few red blood cell precursors

PRCA requires withdrawal of the ESA and specialist management. A worsening red blood cell count during darbepoetin treatment should never be met simply by increasing the dose repeatedly.

Molidustat for Cats

Molidustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor, usually shortened to HIF-PH inhibitor.

Instead of supplying a human EPO analogue, it stabilises the body’s oxygen-sensing pathway and encourages the cat’s own kidneys and other tissues to increase endogenous EPO production.

It may also influence iron handling, although the clinical significance of this effect in feline CKD continues to be studied.

What is Varenzin-CA1?

Varenzin-CA1 is an oral molidustat suspension conditionally approved in the United States for control of nonregenerative anemia associated with CKD in cats.

It is given once daily for up to 28 days, followed by a treatment pause of at least seven days. Additional cycles may be used according to the cat’s hematocrit and the prescribing veterinarian’s instructions.

As of July 2026, the product remains within the FDA expanded conditional approval programme rather than being listed as fully approved. It is labelled for cats, not dogs.

How effective is molidustat?

A 2026 multicentre, randomised field study included 75 cats with CKD-associated anemia.

By day 28:

• Approximately 68% of molidustat-treated cats met the study’s hematocrit response criteria

• Approximately 17% of control cats met those criteria

• Repeated 28-day treatment cycles were generally well tolerated during the continuation phase

Treatment still requires close monitoring because individual cats respond differently and excessive red blood cell production must be avoided.

What are the potential side effects?

Reported concerns include:

• Vomiting

• Reduced appetite

• Increased blood pressure

• Excessively high hematocrit

• Changes in potassium

• Possible seizure risk in susceptible cats

• Possible thromboembolic complications

The cat’s PCV or hematocrit and blood pressure must be monitored according to the prescribing protocol.

Molidustat should not be used simply because a cat has CKD. The anemia must be confirmed as nonregenerative and genuinely associated with kidney disease.

Iron Supplementation

Iron is required to produce hemoglobin.

A patient receiving darbepoetin or another erythropoietic treatment may use available iron rapidly as red blood cell production increases. Iron deficiency can then limit the response.

Iron supplementation may be given:

• Orally

• By injection

• As part of a broader anemia protocol

The choice depends on iron status, gastrointestinal tolerance, severity of deficiency and the medication being used.

Is iron always needed?

Not automatically.

A CKD patient may have:

• Absolute iron deficiency

• Functional iron deficiency

• Adequate iron stores

• Excessive iron from previous supplementation or transfusion

Iron should be used according to laboratory findings and the treatment plan.

Serum iron alone is not enough to guide supplementation. Transferrin saturation, ferritin, reticulocyte hemoglobin and the complete clinical picture may be needed.

Oral iron

Advantages include:

• Easy availability

• No injection

• Lower immediate procedural risk

Limitations include:

• Nausea

• Reduced appetite

• Vomiting

• Constipation or diarrhoea

• Poor absorption

• Interaction with food or other medication

• Limited effectiveness during high-hepcidin inflammatory states

Injectable iron

Injectable preparations bypass intestinal absorption and may be useful in selected patients.

Potential disadvantages include:

• Injection discomfort

• Hypersensitivity reactions

• Incorrect dosing

• Iron overload

• Difficulty assessing total body stores

Human iron supplements should not be given without veterinary instructions. Iron overdose can be toxic.

Does Treating the Kidney Disease Fix the Anemia?

Good CKD management supports the anemia treatment but may not restore adequate EPO production by itself.

A broader renal plan may include:

• Maintaining hydration

• Renal diet therapy

• Phosphorus control

• Blood pressure treatment

• Management of proteinuria

• Potassium supplementation when required

• Treatment of metabolic acidosis

• Nausea control

• Appetite support

• Treatment of infection

• Nutritional support

Phosphate binders manage phosphorus. They do not directly treat anemia.

Acid suppressants and sucralfate treat selected gastrointestinal problems. They are not substitutes for red blood cell support or investigation of blood loss.

Comparing the Main Treatment Options

Treatment	Species	How quickly it works	Main role	Important limitations
Blood transfusion	Dogs and cats	Immediate	Severe symptomatic anemia, active bleeding or emergency stabilisation	Temporary effect, transfusion reactions and fluid overload
Darbepoetin	Dogs and cats	Usually several weeks	Longer-term stimulation of red blood cell production	Injections, hypertension, iron depletion and rare PRCA
Molidustat	Cats only under the US label	Usually measured over several weeks	Oral stimulation of endogenous EPO pathways	Conditional approval, treatment cycles, vomiting, hypertension and excessive hematocrit risk
Iron supplementation	Dogs and cats	Variable	Corrects or prevents iron-limited erythropoiesis	Does not replace EPO and can cause adverse effects or overload
Treatment of contributing disease	Dogs and cats	Depends on cause	Controls blood loss, infection, inflammation or other marrow suppression	Requires identifying the actual contributor

The treatments are not mutually exclusive. A severely anemic cat may receive a transfusion for immediate stabilisation, begin a longer-term anemia medication and receive iron support when indicated.

How Is Treatment Monitored?

Monitoring is essential because both inadequate treatment and excessive treatment can be harmful.

During early treatment

The veterinary team may monitor:

• PCV or hematocrit

• Complete blood count

• Reticulocyte count

• Blood pressure

• Iron status

• Kidney values

• Potassium

• Phosphorus

• Body weight

• Appetite

• Energy

• Breathing

• Medication tolerance

Darbepoetin patients are commonly checked weekly during induction.

Molidustat patients require hematocrit monitoring according to the product protocol, including assessment before beginning another cycle.

Once the patient is stable

Monitoring intervals may be extended, but regular reassessment remains necessary.

The treatment requirement may change because of:

• CKD progression

• Improved iron availability

• New inflammation or infection

• Blood loss

• Medication changes

• Changing body weight

• Reduced appetite

• Development of hypertension

• Excessive hematocrit response

What does a good response look like?

Useful improvements include:

• Rising hematocrit

• Increased reticulocyte response

• Pinker gums

• Better appetite

• Improved energy

• Better mobility

• Reduced resting heart rate

• Improved engagement and quality of life

The objective is not necessarily to push the hematocrit to the upper end of normal. Overcorrection can produce excessive blood viscosity and cardiovascular or thrombotic complications.

Why Might Treatment Fail?

Poor response does not always mean the medication dose is too low.

Possible explanations include:

• Incorrect diagnosis

• Ongoing blood loss

• Iron deficiency

• Functional iron restriction

• Infection

• Chronic inflammation

• Cancer

• Bone marrow disease

• Severe malnutrition

• Inadequate dose or administration

• Progressive CKD

• Pure red cell aplasia

• Poor owner compliance

• Insufficient time for the treatment to work

Inflammation may reduce the response to erythropoietic treatment. A patient that is not improving should be reassessed systematically rather than having the medication increased indefinitely.

What Is the Prognosis?

Renal anemia usually indicates clinically important CKD, but it does not have one fixed prognosis.

The outlook depends on:

• CKD stage

• Severity of anemia

• Speed of progression

• Presence of blood loss

• Iron availability

• Blood pressure

• Appetite and body condition

• Concurrent disease

• Response to treatment

• Ability to tolerate medication

• Development of treatment complications

Anemia is associated with reduced quality of life and poorer survival in CKD populations. Successful treatment can substantially improve appetite, strength, interaction and daily comfort, but it does not cure the underlying kidney disease.

Some patients require treatment for the remainder of their lives. Others improve temporarily after correction of blood loss, infection or iron deficiency and need less intensive support.

When Is Renal Anemia an Emergency?

Go to an emergency veterinary hospital immediately if your dog or cat develops:

• Collapse

• Inability to stand

• Open-mouth breathing

• Marked breathing effort

• Very pale or white gums

• Blue or grey gums

• Reduced consciousness

• Seizures

• Sudden severe weakness

• Rapid deterioration over several hours

• Uncontrolled bleeding

• Vomiting blood

• Black, tar-like stool with weakness

• Large volumes of blood in urine

• A severe reaction during or after transfusion

Seek same-day veterinary care for:

• Rapidly worsening lethargy

• Complete refusal of food

• Increasing breathing rate

• A visibly pale mouth

• New weakness

• A substantially falling hematocrit

• Suspected gastrointestinal bleeding

• Fever or illness during darbepoetin treatment

• Vomiting or neurological signs during molidustat treatment

Minimise stress during transport. Do not force food or water into a weak or poorly responsive patient, and do not give human iron, pain medication or stomach remedies.

What Should You Do Next?

1. Obtain the complete CBC

Ask for:

• Hematocrit or PCV

• Hemoglobin

• Red blood cell count

• Reticulocyte count

• Red blood cell indices

• White blood cell count

• Platelet count

• Blood-smear interpretation

Do not rely only on being told that the pet is “a bit anemic”.

2. Review the trend

Compare the current result with previous blood tests.

Ask:

• Is the anemia stable or progressing?

• How quickly did it change?

• Was the pet dehydrated during either test?

• Has fluid therapy altered the result?

• Has the pet recently lost blood?

3. Confirm whether the severity fits the CKD stage

Marked anemia in early CKD deserves a wider investigation.

Do not allow every low hematocrit in a renal patient to be filed automatically under “the kidneys”.

4. Look for contributing disease

Discuss:

• Iron status

• Urinalysis and culture

• Gastrointestinal bleeding

• Parasites

• Infectious disease

• Cancer screening

• Medication exposure

• Bone marrow investigation when indicated

5. Decide whether immediate stabilisation is needed

Ask whether the patient needs:

• Hospitalisation

• Oxygen

• Transfusion

• Fluids

• Treatment of active bleeding

6. Select a longer-term therapy

Depending on the species, location and clinical situation, discuss:

• Darbepoetin

• Molidustat for cats

• Iron supplementation

• Treatment of concurrent disease

• Supportive CKD care

7. Create a written monitoring plan

The plan should state:

• When the next CBC is due

• When blood pressure will be checked

• Which adverse effects to watch for

• What hematocrit range is being targeted

• What happens if there is no response

• What signs require emergency care

• Who to contact after hours

Common Mistakes Owners Should Avoid

Assuming all anemia in a CKD patient is renal anemia

Blood loss, infection, inflammation, cancer and bone marrow disease remain possible.

Waiting until the PCV falls below 20%

Current IRIS guidance supports treatment earlier than this in both dogs and cats.

Treating every low hematocrit with iron alone

Iron cannot replace the missing EPO signal and may be inappropriate when iron stores are adequate.

Giving human iron supplements

Iron can cause gastrointestinal injury and toxicity. The form and dose must be prescribed.

Assuming a blood transfusion permanently fixes the problem

A transfusion provides temporary red blood cells. It does not restore kidney EPO production.

Expecting darbepoetin to work within a day or two

Meaningful red blood cell production usually takes several weeks.

Increasing darbepoetin when the anemia suddenly worsens

Loss of response may indicate blood loss, iron restriction, inflammation or pure red cell aplasia.

Using stomach medication automatically

Acid suppressants, sucralfate and phosphate binders are not direct treatments for renal anemia.

Skipping blood pressure checks

Both CKD and anemia treatments can be associated with hypertension.

Focusing only on the laboratory result

Appetite, energy, breathing, strength and quality of life are equally important measures of success.

Can Renal Anemia Be Prevented?

Loss of erythropoietin production cannot always be prevented as CKD progresses.

The severity and complications of anemia may be reduced through:

• Regular CBC monitoring

• Early recognition of a falling hematocrit

• Appropriate CKD staging

• Maintaining adequate nutrition

• Treating nausea and appetite loss

• Controlling gastrointestinal or urinary bleeding

• Consistent parasite prevention

• Treating infection promptly

• Monitoring iron status

• Minimising unnecessary blood collection

• Managing inflammation

• Avoiding unprescribed medication and supplements

• Monitoring patients receiving marrow-suppressive medication

The most effective strategy is early recognition rather than waiting for white gums, severe weakness or collapse.

Frequently Asked Questions

What hematocrit requires treatment for renal anemia?

Current IRIS guidance recommends treatment when hematocrit is below 25% in cats or below 30% in dogs. Persistent hematocrit between 25% and 28% in cats, or between 30% and 35% in dogs, should also be treated when CKD is considered the cause.

Can iron alone correct renal anemia?

Usually not. Iron may be an important part of treatment, particularly when deficiency or iron-restricted erythropoiesis is present, but it does not replace inadequate erythropoietin production.

How long does renal anemia treatment take to work?

A blood transfusion works immediately. Darbepoetin commonly takes approximately two to four weeks to produce a meaningful response. Molidustat response is also assessed over several weeks, commonly during a 28-day treatment cycle.

Does every severely anemic kidney patient need a transfusion?

No. Transfusion decisions are based on clinical stability, signs, active bleeding and speed of decline, not one fixed PCV. A stable chronic patient may begin longer-term treatment without transfusion, while a collapsing or breathless patient may require immediate blood support.

Can renal anemia return after successful treatment?

Yes. CKD is progressive, and treatment requirements can change. Anemia may also return because of iron deficiency, inflammation, infection, blood loss, medication changes or loss of response to therapy.

Final Takeaway

Renal anemia develops mainly because diseased kidneys cannot produce an appropriate erythropoietin response, but that is rarely the entire story.

Iron restriction, chronic inflammation, shortened red blood cell survival, poor nutrition and blood loss may all contribute. The anemia must therefore be confirmed as nonregenerative and assessed in the context of the patient’s CKD stage, hydration, reticulocyte response and wider health.

Current IRIS guidance supports treating CKD-associated anemia earlier than many older recommendations:

• Below 25% hematocrit in cats

• Persistent 25% to 28% in cats

• Below 30% in dogs

• Persistent 30% to 35% in dogs

Blood transfusion provides immediate support for an unstable patient. Darbepoetin offers longer-term treatment for dogs and cats, while molidustat provides an oral, conditionally approved option for appropriately selected cats in the United States. Iron and treatment of contributing disease remain important parts of the plan.

The goal is not simply to move one blood value into range. It is to restore enough oxygen-carrying capacity for the pet to eat, move, breathe and interact comfortably while the underlying kidney disease continues to be managed.

---

If you are unsure whether your pet’s PCV, hematocrit, pale gums, weakness or treatment response requires urgent care, ASK A VET™ can help you organise the results and prepare the right questions for your veterinarian.